文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

氟氢可的松联合氢化可的松与单用氢化可的松治疗脓毒性休克:随机对照试验的系统评价与网状Meta分析

Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论在成人脓毒性休克中,氟氢可的松联合氢化可的松较安慰剂和单用氢化可的松与全因死亡率降低相关(RR 0.85、0.88)。

该研究为系统评价与贝叶斯网状Meta分析,纳入17项随机试验共7688例成人脓毒性休克患者,比较氟氢可的松联合氢化可的松、单用氢化可的松与安慰剂或常规治疗。主要终点末次随访全因死亡率在氟氢可的松联合氢化可的松组最低(RR 0.85,95%CrI 0.72-0.99,优越概率98.3%,中等确定性证据),单用氢化可的松组为RR 0.97(95%CrI 0.87-1.07,优越概率73.1%,低确定性证据)。联合方案较单用氢化可的松的全因死亡风险低12%(RR 0.88,95%CrI 0.74-1.03,优越概率94.2%,中等确定性证据),但该比较主要基于间接证据(仅两项试验提供直接证据)。作者指出应结合纳入试验的异质性来理解这些发现。

要点

  • 成人脓毒性休克:氟氢可的松联合氢化可的松较安慰剂或常规治疗降低末次随访全因死亡率(RR 0.85,95%CrI 0.72-0.99,中等确定性证据)。
  • 单用氢化可的松较安慰剂或常规治疗的全因死亡率无统计学显著差异(RR 0.97,95%CrI 0.87-1.07,低确定性证据)。
  • 联合方案较单用氢化可的松的全因死亡风险低12%(RR 0.88,95%CrI 0.74-1.03,优越概率94.2%,中等确定性证据),但该比较主要基于间接证据。
  • 联合方案与单用氢化可的松的直接对比仅两项试验,网状Meta分析主要依赖间接证据。
  • 作者指出应结合纳入试验的异质性来理解这些发现。

适用人群与场景

  • 成人脓毒性休克患者(纳入17项随机试验共7688例)。

研究设计与关键结果

  • 研究类型为系统评价与贝叶斯网状Meta分析,纳入17项随机试验、共7688例成人脓毒性休克患者,比较氟氢可的松联合氢化可的松、单用氢化可的松与安慰剂或常规治疗。
  • 主要终点末次随访全因死亡率:氟氢可的松联合氢化可的松组最低(RR 0.85,95%CrI 0.72-0.99;优越概率98.3%;中等确定性证据)。
  • 单用氢化可的松组末次随访全因死亡率:RR 0.97(95%CrI 0.87-1.07;优越概率73.1%;低确定性证据)。
  • 氟氢可的松联合氢化可的松较单用氢化可的松的全因死亡风险低12%(RR 0.88,95%CrI 0.74-1.03;优越概率94.2%;中等确定性证据)。
  • 氟氢可的松联合氢化可的松与单用氢化可的松的比较主要基于间接证据,仅两项试验提供直接证据。
  • 检索7553条参考文献后纳入17项试验(7688例患者)。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与贝叶斯网状Meta分析;证据确定性:氟氢可的松联合氢化可的松与安慰剂比较为中等确定性证据,单用氢化可的松与安慰剂比较为低确定性证据,联合方案与单用氢化可的松比较为中等确定性证据。
  • 局限:氟氢可的松联合氢化可的松与单用氢化可的松的直接对比试验稀缺,网状Meta分析对该比较主要依赖间接证据;作者指出应结合纳入试验的异质性来理解这些发现。

对床旁实践的改变

  • 对成人脓毒性休克患者,本分析提示氟氢可的松联合氢化可的松较安慰剂或常规治疗与末次随访全因死亡率降低相关(RR 0.85,95%CrI 0.72-0.99,中等确定性证据),单用氢化可的松与安慰剂或常规治疗的全因死亡率无统计学显著差异(RR 0.97,95%CrI 0.87-1.07)。
  • 联合方案较单用氢化可的松的全因死亡风险低12%(RR 0.88,95%CrI 0.74-1.03,中等确定性证据),但该比较主要基于间接证据,作者指出应结合纳入试验的异质性来理解这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: The use of hydrocortisone in adult patients with septic shock is controversial, and the effectiveness of adding fludrocortisone to hydrocortisone remains uncertain. Objectives: To assess the comparative effectiveness and safety of fludrocortisone plus hydrocortisone, hydrocortisone alone, and placebo or usual care in adults with septic shock. Methods: A systematic review and a Bayesian network meta-analysis of peer-reviewed randomized trials were conducted. The primary outcome was all-cause mortality at last follow-up. Treatment effects are presented as relative risks (RRs) with 95% credible intervals (CrIs). Placebo or usual care was the reference treatment. Measurements and Main Results: Among 7,553 references, we included 17 trials (7,688 patients). All-cause mortality at last follow-up was lowest with fludrocortisone plus hydrocortisone (RR, 0.85; 95% CrI, 0.72-0.99; 98.3% probability of superiority, moderate-certainty evidence), followed by hydrocortisone alone (RR, 0.97; 95% CrI, 0.87-1.07; 73.1% probability of superiority, low-certainty evidence). The comparison of fludrocortisone plus hydrocortisone versus hydrocortisone alone was based primarily on indirect evidence (only two trials with direct evidence). Fludrocortisone plus hydrocortisone was associated with a 12% lower risk of all-cause mortality compared with hydrocortisone alone (RR, 0.88; 95% CrI, 0.74-1.03; 94.2% probability of superiority, moderate-certainty evidence). Conclusions: In adult patients with septic shock, fludrocortisone plus hydrocortisone was associated with lower risk of all-cause mortality at last follow-up than placebo and hydrocortisone alone. The scarcity of head-to-head trials comparing fludrocortisone plus hydrocortisone versus hydrocortisone alone led our network meta-analysis to rely primarily on indirect evidence for this comparison. Although we undertook several sensitivity analyses and assessments, these findings should be considered while also acknowledging the heterogeneity of included trials.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Teja B, Berube M, Pereira TV, et al. Effectiveness of Fludrocortisone Plus Hydrocortisone versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Am J Respir Crit Care Med. 2024. PMID: 38271488. doi:10.1164/rccm.202310-1785OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。